USP7抑制剂的研究进展  

Research Progress of USP7 Inhibitors

作　　者：郑欣 董茹 周鑫 王敏[1] 孙丽萍[1] Zheng Xin;Dong Ru;Zhou Xin;Wang Min;Sun Liping(China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学,江苏南京211198

出　　处：《广东化工》2020年第18期94-96,共3页Guangdong Chemical Industry

摘　　要：泛素特异性蛋白酶7(Ubiquitin-specific protease 7,USP7)是去泛素化酶(Deubiquitinases,DUBs)家族中的一员。约50%的人类癌症中抑癌基因TP53发生了突变,细胞内p53不正常表达,导致细胞凋亡等正常生命活动紊乱。USP7与p53以及HDM2有着密切的联系,USP7是p53的上游蛋白,所以调控USP7能达到调控p53的目的。并且许多癌症也与USP7的不正常表达有关。Ubiquitin-specific protease 7(USP7)is a member of the Deubiquitinases(DUBs)family.In about 50%of human cancers,the tumor suppressor gene TP53 is mutated,and p53 is not normally expressed in cells,leading to disorders of normal life activities such as apoptosis.USP7 is closely related to p53 and HDM2.USP7 is the upstream protein of p53,so regulating USP7 can achieve the purpose of regulating p53.And many cancers are also related to abnormal expression of USP7.

关 键 词：泛素特异性蛋白酶7 P53 去泛素化酶 

分 类 号：TQ[化学工程]